
What else can AI fix? Applications in indication expansion and repurposing
Ben Sidders, Chief Scientific Officer at Biorelate, explores how emerging AI-driven technologies are revealing hidden cause-and-effect relationships within existing biomedical data. Nearly 30% of FDA-approved drugs eventually gain additional indications beyond their original approval and are some of the highest-value and most challenging assessments in drug development. Indication expansion is… Read More















